参芪扶正注射液对肾功能影响的临床实效分析研究(3)
(1. Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences， Beijing 100700， China；
2. Guangdong Hospital of Chinese Medicine， Guanzhou 510120， China；
3. School of Statistics， Renmin University of China， Beijing 100872， China)
[Abstract] This study analyzes the clinical effects of parenterally administered Shenqi Fuzheng on renal function. 20 national， general hospitals were selected. Their hospital information system (HIS) data on 51 898 cases of parenterally administered Shenqi Fuzheng were mined for data. Patients ranged from 18 to 80 years old. 27 718 cases were selected for analysis. Serum creatinine (Scr) and blood urea nitrogen (BUN) levels were taken before and after treatment for outcome evaluation. According to instructions， we divided 197 cases into the treatment group (doses> 250 mL) and 5 728 cases acted as the control group (dose ≤ 250 mL). Stratified analysis adjusted for age， sex， hospital illness， treatment， etc. According to the four variables， the case group compared with the control group did not show abnormal renal function changes； 57 confounding factors were balanced using propensity score method resulting in the treatment group showing no abnormal changes in renal function. This HIS b data analysis found that parenterally administered Shenqi Fuzheng above the recommended dosage did not significantly impact on renal function was no significant difference. Prospective studies should be carried out to validate this data.
[Key words] parenterally administered Shenqi Fuzheng； dosage； renal function； propensity score； clinical research
doi：10.4268/cjcmm20131823, http://www.100md.com(黎元元 赵敏 谢雁鸣 李霖 尤丽)
2. Guangdong Hospital of Chinese Medicine， Guanzhou 510120， China；
3. School of Statistics， Renmin University of China， Beijing 100872， China)
[Abstract] This study analyzes the clinical effects of parenterally administered Shenqi Fuzheng on renal function. 20 national， general hospitals were selected. Their hospital information system (HIS) data on 51 898 cases of parenterally administered Shenqi Fuzheng were mined for data. Patients ranged from 18 to 80 years old. 27 718 cases were selected for analysis. Serum creatinine (Scr) and blood urea nitrogen (BUN) levels were taken before and after treatment for outcome evaluation. According to instructions， we divided 197 cases into the treatment group (doses> 250 mL) and 5 728 cases acted as the control group (dose ≤ 250 mL). Stratified analysis adjusted for age， sex， hospital illness， treatment， etc. According to the four variables， the case group compared with the control group did not show abnormal renal function changes； 57 confounding factors were balanced using propensity score method resulting in the treatment group showing no abnormal changes in renal function. This HIS b data analysis found that parenterally administered Shenqi Fuzheng above the recommended dosage did not significantly impact on renal function was no significant difference. Prospective studies should be carried out to validate this data.
[Key words] parenterally administered Shenqi Fuzheng； dosage； renal function； propensity score； clinical research
doi：10.4268/cjcmm20131823, http://www.100md.com(黎元元 赵敏 谢雁鸣 李霖 尤丽)